TWI592406B - 嘧啶酪氨酸激酶抑制劑 - Google Patents

嘧啶酪氨酸激酶抑制劑 Download PDF

Info

Publication number
TWI592406B
TWI592406B TW102120447A TW102120447A TWI592406B TW I592406 B TWI592406 B TW I592406B TW 102120447 A TW102120447 A TW 102120447A TW 102120447 A TW102120447 A TW 102120447A TW I592406 B TWI592406 B TW I592406B
Authority
TW
Taiwan
Prior art keywords
compound
amino
mixture
oxo
chloro
Prior art date
Application number
TW102120447A
Other languages
English (en)
Chinese (zh)
Other versions
TW201410668A (zh
Inventor
布萊恩Ｔ 哈柏金
派翠克 科隆
提摩西Ｒ 查
崔西Ｊ 傑金斯
席衛 凱
翔林 辛
羅斯Ａ 米勒
安德魯 湯普森
Original Assignee
百健Ｍａ公司
桑西斯醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 百健Ｍａ公司, 桑西斯醫藥公司 filed Critical 百健Ｍａ公司
Publication of TW201410668A publication Critical patent/TW201410668A/zh
Application granted granted Critical
Publication of TWI592406B publication Critical patent/TWI592406B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TW102120447A 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑 TWI592406B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08

Publications (2)

Publication Number Publication Date
TW201410668A TW201410668A (zh) 2014-03-16
TWI592406B true TWI592406B (zh) 2017-07-21

Family

ID=49712704

Family Applications (3)

Application Number Title Priority Date Filing Date
TW102120447A TWI592406B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑
TW110102365A TWI792158B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑
TW106116775A TWI719209B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110102365A TWI792158B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑
TW106116775A TWI719209B (zh) 2012-06-08 2013-06-07 嘧啶酪氨酸激酶抑制劑

Country Status (30)

Country Link
US (6) US9394277B2 (cg-RX-API-DMAC10.html)
EP (3) EP2858499B1 (cg-RX-API-DMAC10.html)
JP (6) JP6214643B2 (cg-RX-API-DMAC10.html)
KR (4) KR102468430B1 (cg-RX-API-DMAC10.html)
CN (3) CN109305959B (cg-RX-API-DMAC10.html)
AR (1) AR091273A1 (cg-RX-API-DMAC10.html)
AU (5) AU2013271407B2 (cg-RX-API-DMAC10.html)
BR (2) BR122021002178B1 (cg-RX-API-DMAC10.html)
CA (2) CA3108186A1 (cg-RX-API-DMAC10.html)
CY (1) CY1120638T1 (cg-RX-API-DMAC10.html)
DK (1) DK2858499T3 (cg-RX-API-DMAC10.html)
EA (2) EA027823B1 (cg-RX-API-DMAC10.html)
ES (2) ES2834333T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20181294T1 (cg-RX-API-DMAC10.html)
HU (1) HUE039897T2 (cg-RX-API-DMAC10.html)
IL (2) IL235938B (cg-RX-API-DMAC10.html)
IN (1) IN2014DN10576A (cg-RX-API-DMAC10.html)
LT (1) LT2858499T (cg-RX-API-DMAC10.html)
MX (2) MX385593B (cg-RX-API-DMAC10.html)
NZ (1) NZ702715A (cg-RX-API-DMAC10.html)
PH (2) PH12018501463B1 (cg-RX-API-DMAC10.html)
PL (1) PL2858499T3 (cg-RX-API-DMAC10.html)
PT (1) PT2858499T (cg-RX-API-DMAC10.html)
RS (1) RS57978B1 (cg-RX-API-DMAC10.html)
SG (2) SG10201708535UA (cg-RX-API-DMAC10.html)
SI (1) SI2858499T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201800442T1 (cg-RX-API-DMAC10.html)
TW (3) TWI592406B (cg-RX-API-DMAC10.html)
WO (1) WO2013185084A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201409255B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719209B (zh) * 2012-06-08 2021-02-21 美商百健Ｍａ公司 嘧啶酪氨酸激酶抑制劑

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2473049T3 (pl) * 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
AR098721A1 (es) * 2013-12-11 2016-06-08 Biogen Idec Inc Inhibidores de biarilo de tirosina quinasa de bruton
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
CA2965517C (en) * 2014-10-24 2023-05-02 Bristol-Myers Squibb Company Indole carboxamides compounds useful as kinase inhibitors
WO2018017153A1 (en) * 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
WO2020028258A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
CZ20023033A3 (cs) 2000-03-17 2003-01-15 Bristol-Myers Squibb Pharma Company Deriváty cyklických beta-aminokyselin jako inhibitory matrixových metaloproteáz a TNF-alfa
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
CA2412560C (en) 2000-06-26 2008-12-30 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AU2004282179B2 (en) 2003-10-14 2011-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
WO2006073419A2 (en) * 2004-04-01 2006-07-13 Gang Zheng Lipoprotein nanoplatforms
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
TW200621760A (en) 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
US7528138B2 (en) * 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
PE20071162A1 (es) * 2005-12-21 2007-11-30 Schering Corp Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
US20080076924A1 (en) 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
EP2059305A2 (en) 2006-07-26 2009-05-20 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
WO2009134891A2 (en) 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
JP2010520199A (ja) * 2007-03-02 2010-06-10 シェーリング コーポレイション ピペリジン誘導体およびその使用方法
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
BRPI0811898A2 (pt) 2007-06-01 2019-09-24 Glaxosmithkline Llc composto, composição farmacêutica, métodos para tratar um neoplasma suscetível e um câncer em um mamífero, processo para preparar um composto, e, uso de um composto.
JP5259739B2 (ja) 2008-02-05 2013-08-07 エフ．ホフマン−ラ ロシュ アーゲー 新規ピリジノン及びピリダジノン
JP5369183B2 (ja) * 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
SG171815A1 (en) * 2008-12-19 2011-07-28 Bristol Myers Squibb Co Carbazole carboxamide compounds useful as kinase inhibitors
WO2010080712A2 (en) * 2009-01-06 2010-07-15 Dana Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
JP2012528103A (ja) 2009-05-25 2012-11-12 サンド・アクチエンゲゼルシヤフト セフトビプロールメドカリルの製造方法
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
US8685880B2 (en) * 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
AR098721A1 (es) 2013-12-11 2016-06-08 Biogen Idec Inc Inhibidores de biarilo de tirosina quinasa de bruton
WO2015089327A1 (en) 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US20170298446A1 (en) 2014-10-03 2017-10-19 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
WO2018017153A1 (en) * 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719209B (zh) * 2012-06-08 2021-02-21 美商百健Ｍａ公司 嘧啶酪氨酸激酶抑制劑

Also Published As

Publication number Publication date
AU2013271407B2 (en) 2016-12-08
JP2021073299A (ja) 2021-05-13
CA3108186A1 (en) 2013-12-12
PH12018501463B1 (en) 2024-03-27
US20190047986A1 (en) 2019-02-14
JP2023052415A (ja) 2023-04-11
KR20220154850A (ko) 2022-11-22
US9944622B2 (en) 2018-04-17
AU2019203476B2 (en) 2021-01-28
MX385593B (es) 2025-03-18
JP2021073298A (ja) 2021-05-13
US20240417389A1 (en) 2024-12-19
ES2834333T3 (es) 2021-06-17
SI2858499T1 (sl) 2018-10-30
EP3385263B1 (en) 2020-07-22
TW201805279A (zh) 2018-02-16
IL277951A (en) 2020-11-30
EP2858499A1 (en) 2015-04-15
ES2684268T3 (es) 2018-10-02
PH12014502699A1 (en) 2015-02-02
US20210017155A1 (en) 2021-01-21
RS57978B1 (sr) 2019-01-31
HRP20181294T1 (hr) 2018-10-05
EP3753934A1 (en) 2020-12-23
HUE039897T2 (hu) 2019-02-28
EA027823B1 (ru) 2017-09-29
WO2013185084A1 (en) 2013-12-12
ZA201409255B (en) 2015-12-23
CN113549055A (zh) 2021-10-26
TWI719209B (zh) 2021-02-21
AU2017201536A1 (en) 2017-03-23
MX363672B (es) 2019-03-29
PT2858499T (pt) 2018-10-24
BR112014030655A2 (pt) 2017-06-27
IL235938B (en) 2020-10-29
US10618887B2 (en) 2020-04-14
US20230174511A1 (en) 2023-06-08
AU2019203476A1 (en) 2019-06-06
SMT201800442T1 (it) 2018-09-13
CN109305959B (zh) 2022-02-08
PH12018501463A1 (en) 2019-03-04
IL235938A0 (en) 2015-02-01
CN109305959A (zh) 2019-02-05
DK2858499T3 (en) 2018-08-20
TW201410668A (zh) 2014-03-16
AU2013271407A1 (en) 2015-01-22
EP2858499A4 (en) 2016-01-20
JP2019077728A (ja) 2019-05-23
AU2022275504A1 (en) 2023-01-05
EA201790418A1 (ru) 2017-11-30
JP2015518903A (ja) 2015-07-06
BR112014030655A8 (pt) 2018-01-02
BR112014030655B1 (pt) 2021-04-20
CA2875799C (en) 2021-03-23
PL2858499T3 (pl) 2019-03-29
AR091273A1 (es) 2015-01-21
KR102468430B1 (ko) 2022-11-21
AU2021202412A1 (en) 2021-05-20
JP6214643B2 (ja) 2017-10-18
TWI792158B (zh) 2023-02-11
KR20200043497A (ko) 2020-04-27
PH12014502699B1 (en) 2015-02-02
HK1209284A1 (en) 2016-04-01
KR20210072139A (ko) 2021-06-16
BR122021002178B1 (pt) 2022-03-22
KR20150036020A (ko) 2015-04-07
MX2019003618A (es) 2019-07-18
US20160304494A1 (en) 2016-10-20
TW202142535A (zh) 2021-11-16
CY1120638T1 (el) 2019-12-11
JP2017193583A (ja) 2017-10-26
EP3385263A1 (en) 2018-10-10
EP2858499B1 (en) 2018-05-16
LT2858499T (lt) 2018-09-10
NZ702715A (en) 2016-11-25
SG11201408173WA (en) 2015-01-29
IN2014DN10576A (cg-RX-API-DMAC10.html) 2015-08-28
SG10201708535UA (en) 2017-11-29
CN104540385A (zh) 2015-04-22
AU2017201536B2 (en) 2019-03-07
US9394277B2 (en) 2016-07-19
CA2875799A1 (en) 2013-12-12
MX2014015044A (es) 2015-09-22
KR102102587B1 (ko) 2020-04-22
CN104540385B (zh) 2018-06-05
US20150158843A1 (en) 2015-06-11
EA201492056A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
TWI592406B (zh) 嘧啶酪氨酸激酶抑制劑
HK40043767A (en) Pyrimidinyl derivatives useful as tyrosine kinase inhibitors
HK1262106A1 (en) Pyrimidinyl tyrosine kinase inhibitors
HK1262106B (en) Pyrimidinyl tyrosine kinase inhibitors
HK1209284B (zh) 嘧啶基酪氨酸激酶抑制劑

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees